Market News & Trends
BD Completes Clinical Trial for Wearable Injector
BD (Becton, Dickinson and Company), a leading global medical technology company, recently announced the completion of a 50-subject human clinical trial with the BD Libertas…
Zumutor Biologics & Catalent Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
Catalent recently announced it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor…
BeyondSpring’s Plinabulin Stimulates Both the Adaptive & Innate Immune System
BeyondSpring Inc. recently announced that new clinical data on the company’s first-in-class, late-stage asset, Plinabulin, shows its ability to potently stimulate the innate immune system.…
Biologics Patent Expiry Trend Expected to Have Positive Impact
Expectations for biosimilars are high in 2020, and the drug class will finally begin to make its mark in the US, says GlobalData, a leading…
Stevanato Group & Bormioli Pharma Sign Collaboration Agreement
Stevanato Group, through Ompi, its specialist in glass primary packaging for the pharmaceutical industry, and Bormioli Pharma recently announced a collaboration agreement that will enable…
Synteract Expands Into Asia Pacific & South Africa Through Acquisition of Specialty Biometrics CRO
Synteract recently acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint…
CURE Pharmaceutical Signs Exclusive Licensing Agreement With ReLeaf Europe
CURE Pharmaceutical recently announced it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.…
AskBio Announces First Patient Dosed in Phase 1 Trial
Asklepios BioPharmaceutical (AskBio) and its NanoCor Therapeutics subsidiary recently announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101.…
Cellectricon & StressMarq Biosciences Collaborate to Develop Next-Generation Reagents & Assays
Cellectricon recently announced a collaboration with StressMarq Biosciences. As a supplier of life science reagents such as primary antibodies, antibody conjugates, proteins, immunoassay kits and…
Ubiquigent Launches a New Service to Facilitate Target Validation of DUB Enzymes & Determine Compound-DUB Target Engagement & Selectivity of Novel Compounds in Cells
Ubiquigent Limited (Ubiquigent) recently announced the launch of an exciting new service as part of its Drug Discovery Screening Platform – DUBprofiler-Cell. DUBprofiler-Cell supports the…